We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase III Study on HMPL-523 for Treatment of ITP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05029635
Recruitment Status : Not yet recruiting
First Posted : August 31, 2021
Last Update Posted : August 31, 2021
Information provided by (Responsible Party):
Hutchmed ( Hutchison Medipharma Limited )

Brief Summary:
This is a randomized, double blinded, placebo-controlled phase III clinical trial in adult patients with immune thrombocytopenia.

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia (ITP) Drug: HMPL-523 Drug: Placebo Phase 3

Detailed Description:
Approximate 177 patients will be enrolled in study (HMPL-523 2:1 vs Placebo) .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 177 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults
Estimated Study Start Date : October 1, 2021
Estimated Primary Completion Date : November 30, 2023
Estimated Study Completion Date : November 30, 2023

Arm Intervention/treatment
Active Comparator: treatment arm
Eligible subjects will be treated with planned dose of 300 mg HMPL-523 once daily for 24 weeks
Drug: HMPL-523
HMPL-523 will be oral administrated once daily for 24 weeks

Placebo Comparator: placebo arm
Drug: Placebo HMPL-523 matching placebo will be oral administrated once daily for 24 weeks.
Drug: Placebo
HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .

Primary Outcome Measures :
  1. the durable response rate in the primary study [ Time Frame: treatment period Week14-Week24 ]
    Platelet count ≥50×10^9 /L on at least 4 of 6 scheduled visits of Week14-Week24 in the primary study

Secondary Outcome Measures :
  1. the overall response rate in the primary study [ Time Frame: treatment period Week1-Week24 in the primary study ]
    At least one platelet count ≥50×10^9 /L (except that induced by the rescue therapy) in the 24-week double-blind treatment period

  2. Incidence of treatment emergent adverse events [ Time Frame: treatment period Week1-Week24 in the primary study ]
    Adverse events classified according to NCI CTCAE version 5.0

  3. Plasma concentration at steady state 2 hours post dose (C2h,ss) [ Time Frame: treatment period Week1-Week24 in the primary study ]
    Plasma concentration of HMPL-523 and its main metabolites at steady state 2 hours post dose (C2h,ss) will be determined.

  4. Plasma concentration at steady state 2 hours post dose (C4h,ss) [ Time Frame: treatment period Week1-Week24 in the primary study ]
    Plasma concentration of HMPL-523 and its main metabolites at steady state 4 hours post dose (C4h,ss) will be determined.

  5. Plasma concentration at steady-state trough concentration (Cmin,ss) [ Time Frame: treatment period Week1-Week24 in the primary study ]
    Plasma concentration of HMPL-523 and its main metabolites at steady-state trough concentration (Cmin,ss) will be determined.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Voluntary signature of written informed consent form;
  2. Male or female aged 18~75 years;
  3. Performance Status score [Eastern Cooperative Oncology Group (ECOG) score] 0~1;
  4. Having been diagnosed as ITP prior to randomization, and duration of disease is more than 6 months;
  5. Intolerance or insufficient response, or recurrence after at least one anti-ITP standard drug therapy;
  6. Patients must have a history of response to previous ITP therapy;
  7. One combined anti-ITP therapy is allowed in this study, however, the following criteria need to be met:

    1. The dose of glucocorticoid has been stable for 4 weeks prior to randomization (<20 mg Prednisone equivalent);
    2. The dose of Danazol has been stable for 3 months prior to randomization;
    3. The dose of immunosuppressant (only including Azathioprine, Ciclosporin A, Mycophenolate mofetil) has been stable for 3 months prior to randomization.
  8. The condition is relatively stable; WHO bleeding scale grade is 0-1; no emergency treatment is expected within 2 weeks as judged by investigators.
  9. The laboratory examinations need to meet the following conditions (no treatment for this abnormal variable is given within one week prior to blood collection):

    1. Platelet count <30×109 /L for twice (at an interval of more than 24 hours) in screening period (except that induced by rescue therapy);
    2. Hemoglobin ≥100 g/L, neutrophil count >1.5×109/L;
    3. Total bilirubin (TBIL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×upper limit of normal (ULN);
    4. Serum creatinine concentration ≤1.5×ULN and creatinine clearance ≥50 mL/min;
    5. Serum amylase and lipase ≤1.5×ULN;
    6. International normalized ratio (INR), activated partial thromboplastin time (APTT) not exceeding 20% of normal range.
  10. Male or female patients of childbearing potential must agree to use effective contraceptive methods during the study and within 90 days after last dose of study drug, e.g., double barrier contraceptive method, condom, oral or injectable contraceptives, intrauterine device, etc. Postmenopausal women (>50 years old and no menses for >1 year) and surgically sterilized women are not subject to this condition.

Exclusion Criteria:

  1. Evidence on the presence of secondary causes of immune thrombocytopenia (e.g., previous history of untreated helicobacter pylori infection, leukemia, lymphoma, common variable immunodeficiency, systemic lupus erythematosus and autoimmune thyroid disorder), or drug therapy (e.g., heparin, quinine, antimicrobial drugs, anticonvulsants), or multiple immune hemocytopenia in the participants, e.g., Evan's syndrome;
  2. Clinically serious hemorrhage requiring immediate adjustment of platelet (e.g., hypermenorrhea with significantly decreased hemoglobin);
  3. Clinically symptomatic gastrointestinal hemorrhage within 6 months prior to screening visit (e.g., haematemesis, tarry stool, however, the positive occult blood test without any sign or symptom of gastrointestinal hemorrhage will not be considered as "clinically symptomatic", or hemorrhoids hemorrhage is one exception);
  4. known history of vital organ transplantation or hematopoietic stem cell / bone marrow transplantation;
  5. Has received live vaccine within 8 weeks prior to Day 1 (baseline visit); or plan for immunization with live vaccine during the study;
  6. Splenectomy within 12 weeks prior to randomization;
  7. Major surgery within 4 weeks prior to the randomization, or plan for major elective surgery during the study;
  8. Previous history of malignant tumors (except for the basal cell carcinoma of skin or cervical carcinoma in situ that have been cured);
  9. History of important arterial / venous embolic disease;
  10. Intracranial hemorrhage within 6 months before screening visit;
  11. History of serious cardiovascular disease (e.g., grade III/IV congestive heart failure, arrhythmia or angina pectoris requiring drug therapy, unstable angina pectoris, intracoronary stent implantation, angioplasty or coronary artery bypass grafting, or QTc ≥450 ms);
  12. Hypertension that can not be controlled with drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
  13. Previous history of serious gastrointestinal disease, such as dysphagia, active gastric ulcer, inability to take drugs orally or absorption disorder for oral drugs;
  14. Human immunodeficiency virus (HIV) infection, or hepatitis B (in case of positive HBsAg or HBcAb, positive HBV DNA needs to be determined), or hepatitis C (positive HCV RNA), or liver cirrhosis;
  15. Significant active infection that is not controlled clinically (e.g., sepsis, pneumonia or abscess), or serious infection within 6 weeks prior to randomization (leading to hospitalization or requiring treatment with antibiotic injections);
  16. Has received rescue therapy for ITP within 2 weeks prior to randomization;
  17. Has received the treatment for the objective of increasing platelet within 4 weeks prior to randomization (including but not limited to glucocorticoid, thrombopoietin, thrombopoietin receptor agonist, Cyclosporine A, Mycophenolate mofetil, etc.), except those meeting the inclusion criterion 7;
  18. Having received Rituximab within 14 weeks prior to randomization;
  19. Having received traditional Chinese medicine within 1 week prior to randomization;
  20. Requiring long-term/continuous use of the drugs that may affect platelet function [including but not limited to aspirin, Clopidogrel, ticagrelor, NSAIDs, etc.], or anticoagulants;
  21. Intake of potent CYP3A inhibitor or inducer, as well as sensitive or narrow therapeutic window substrates of CYP3A, CYP1A2 or CYP2B6 two weeks (three weeks for Hypericum perforatum) or 5 half-lives prior to randomization (whichever is longer);
  22. Having participated in the clinical study for drugs or invasive medical device 4 weeks prior to randomization (or within 5 half-lives of the study drug prior to randomization, whichever is longer);
  23. Having received spleen tyrosine kinase Syk inhibitor (e.g., Fostamatinib) previously;
  24. Known allergy to the active ingredient or excipient of study drug;
  25. Presence of serious psychological or mental disorder;
  26. Alcoholic or drug abuser;
  27. Female patients in pregnancy or breast feeding;
  28. Being unsuitable to participate in this study, as considered by investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05029635

Layout table for location contacts
Contact: Hongyan Yin 201-20671823 hongyany@hutch-med.com

Sponsors and Collaborators
Hutchison Medipharma Limited
Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited
ClinicalTrials.gov Identifier: NCT05029635    
Other Study ID Numbers: 2020-523-00CH1
First Posted: August 31, 2021    Key Record Dates
Last Update Posted: August 31, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Skin Manifestations